|
Canada-0-FreightForwarding 公司名錄
|
公司新聞:
- New Hope for Hard-to-Treat Myasthenia Gravis - Medscape
New phase 3 data show meaningful improvement in antibody-negative myasthenia gravis, for which treatment options are limited and patients face persistent unmet clinical needs
- Myasthenia Gravis Treatment: 5 Things to Know - Medscape
Myasthenia gravis (MG) is a rare, acquired autoimmune disorder of the neuromuscular junction, characterized by fatigable muscle weakness in the voluntary muscles Most patients with MG present
- Key Updates in Myasthenia Gravis From AANEM 2025 - Medscape
Myasthenia gravis updates from AANEM 2025 include efficacy data for efgartigimod, telitacicept, and gefurulimab, plus interim results for a CAR T-cell therapy and DNTH10, an active C1S inhibitor
- Early Detection of MG May Lessen Symptom Severity - Medscape
Early detection of myasthenia gravis, along with timely treatment, could mitigate symptom severity and optimize outcomes, reports Dr Nicholas Silvestri
- Positive Topline Results for Efgartigimod in Ocular MG
Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial
- Myasthenia Gravis: Which Test Is Best? When and Why?
Drs Nicholas Silvestri and Carolina Barnett-Tapia discuss what you need to know about immunopathogenesis and diagnosis for this relatively rare condition
- Myasthenia Gravis Med Tied to Major Reduction in Steroid Use
18-month data show patients with generalized myasthenia gravis taking efgartigimod were able to reduce glucocorticoids to low levels or discontinue them
- Myasthenia Gravis: What Role Does Heredity Play? - Medscape
SAVANNAH, GEORGIA — One patient with autoimmune myasthenia gravis (MG) has a niece with the same diagnosis, and at least one of his other close relatives may have it too Another patient with MG
- Durable Benefit for Nipocalimab in gMG Across Age Groups
Two open-label extension studies show that the FcRn blocker nipocalimab has durable efficacy and sustained symptom control for generalized myasthenia gravis in both teens and adults
|
|